Can Actuate Therapeutics (ACTU) Stock Reach $9.20?

Key Takeaways

• The central target of $9.20 is the arithmetic mean of five verified analyst price targets, ranging widely from $5.00 to $15.00.
• With shares recently trading near $0.81, reaching $9.20 would require upside of roughly 1,035% — a very large move.
• Coverage is unanimous on the buy side, but firms have been cutting targets sharply as the stock has fallen, and the wide $5–$15 range signals major disagreement.
• The strongest supporting factor is the lead drug candidate elraglusib, a GSK-3β inhibitor in Phase 2 development for hard-to-treat cancers.
• The biggest risk is financial: the company has disclosed substantial doubt about its ability to continue as a going concern, with limited cash runway.

Analyst Price Targets and Consensus View

Actuate Therapeutics, Inc. (ACTU) is a clinical-stage biopharmaceutical company based in Fort Worth, Texas, with no approved products and no commercial revenue. It has a small but active sell-side following, and the five current analyst price targets reviewed here produce a wide, top-heavy range.

The individual targets used are: H.C. Wainwright at $15.00 (Buy), Craig-Hallum at $12.00 (Buy), B. Riley Securities at $8.00 (Buy), Rodman & Renshaw at $6.00 (initiated Buy in July 2026), and Lucid Capital at $5.00 (Buy, trimmed from $6.00 in May 2026). The arithmetic mean of these five figures is $9.20, which is the central target used here.

The range is unusually wide — $5.00 to $15.00 — reflecting genuine uncertainty about a pre-revenue biotech. Analysts have been revising downward: H.C. Wainwright cut its target from $20 to $15 in April 2026, and B. Riley lowered its view from $20 to $8. Importantly, several of these targets predate the company's disclosure of going-concern risk, so they may not yet reflect the latest liquidity picture. None of these figures should be read as a guarantee, and the mean is not an official published consensus.

Current Market Position and Path Toward the Target

Shares of ACTU recently traded around $0.81, near the low end of a 52-week range of roughly $0.60 to $8.49, with a market capitalization of only about $19–24 million. The stock has fallen roughly 88% over the past year, a decline that has far outpaced any downward revision in analyst targets.

To reach $9.20, the stock would need to gain about 1,035%, a very large move by any standard. Even the lowest published target of $5.00 implies more than 500% upside. The path toward such a level would depend almost entirely on clinical and financial catalysts rather than near-term fundamentals, because the company currently generates no product revenue and reports ongoing net losses.

What Could Support a Move Toward the Target

The core bull case rests on elraglusib, a small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β). The drug is being studied in Phase 2 trials for metastatic pancreatic ductal adenocarcinoma and in earlier-stage programs for pediatric cancers, melanoma, and colorectal cancer. Positive efficacy or safety data, a favorable regulatory interaction, or a partnership or licensing deal could materially re-rate the shares.

Analysts who maintain Buy ratings generally frame ACTU as a high-risk, high-reward binary on clinical success. Successful financing to extend the cash runway would also remove a major overhang and could support the stock forecast.

What Could Prevent the Target From Being Reached

The dominant risk is financial. Actuate has disclosed substantial doubt about its ability to continue as a going concern, reporting only about $4.4 million in cash as of June 30, 2026 — enough to fund operations into September 2026. Without new capital, the company may be unable to advance elraglusib, which would undermine the entire price forecast.

Additional obstacles include the absence of revenue, a small workforce (roughly a dozen employees), the historical failure rate of oncology drug candidates, and the possibility of dilution if financing is raised at depressed share prices. The sharp decline in the shares and the downward drift in analyst price targets both signal that the market is pricing in meaningful risk.

Technical Levels and Market Structure

From a technical standpoint, ACTU is in a deep, long-term downtrend, trading near the bottom of its 52-week range. The $1.00 level now acts as a psychological resistance zone, with prior support areas from earlier in the year sitting far above the current price. There is no meaningful technical basis near current levels that would point toward the $9.20 target; any move of that magnitude would likely require a fundamental catalyst rather than chart momentum.

Time Horizon and What Investors Should Monitor

Analyst price targets for biotech names typically reflect a roughly 12-month research horizon, though individual firms may use different assumptions, and none of the targets reviewed here should be treated as a timing forecast. Investors should monitor financing announcements and cash position, the next earnings report (estimated around mid-November 2026), elraglusib trial updates, any partnership or licensing developments, and further analyst target revisions. For a pre-revenue biotech, the liquidity situation is the most time-sensitive variable.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For a volatile, low-priced name like ACTU, automated signal monitoring can help surface momentum shifts as they develop.

Final Assessment

The central target of $9.20 — the arithmetic mean of five analyst price targets ranging from $5.00 to $15.00 — implies roughly 1,035% upside from a recent price near $0.81. The bull case hinges on clinical progress for elraglusib and on securing financing, while the bear case centers on going-concern risk, limited cash runway, and the absence of revenue. The unusually wide target range and the pattern of downward revisions underscore how uncertain the outcome remains. Whether ACTU can approach $9.20 depends far more on forthcoming financing and trial developments than on current fundamentals, and no outcome is assured.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations